Get started
Author

Anna Jonášová

Observed names: A Jonášová, A. Jonasova, A. Jonásˇová, A. Jonášová, Anna Jonasova, Anna Jónásová
OpenAlex ID: A5009708162
164 Promising cyclosporin a therapy for myelodysplastic syndrome
1997 · A. Jonásˇová, R. Neuwirtová, et al. · Leukemia Research · 6
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
2026 · Prithviraj Bose, Haris Ali, et al. · Journal of Clinical Oncology · 4
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy
2026 · Andrew T. Kuykendall, Aniket Bankar, et al. · Journal of Clinical Oncology · 3
Safety, tolerability, and pharmacokinetics (PK) of luspatercept (LUSPA) at increased injection volumes (up to 2 mL) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) who require red blood cell (RBC) transfusions: Results from MAXILUS.
2026 · Ali McBride, Krzysztof Madry, et al. · JCO Oncology Practice
PDF
Overall survival and long-term outcomes from the randomized, double-blind, placebocontrolled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes
2026 · Valeria Santini, Rami S. Komrokji, et al. · Haematologica
Variant-specific SF3B1 mutations drive distinct splicing and mitochondrial dysfunction in myelodysplastic neoplasms
2026 · Andrea Hruštincová, Iva Trsová, et al. · Human Genomics
Additional file 1 of Variant-specific SF3B1 mutations drive distinct splicing and mitochondrial dysfunction in myelodysplastic neoplasms
2026 · Andrea Hruštincová, Iva Trsová, et al. · Figshare
450. výročie príchodu Petra Bornemiszu do Šintavy
2024 · Anna Jónásová · Knižnica Časopis pre knihovníctvo
PDF
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS
2023 · A. Dezern, P. Fenaux, et al. · Leukemia Research
Topic: AS07-Singular Entities/Subtypes/AS07d-MDS with ring sideroblasts: SF3B1 MUTATIONS AND THEIR IMPACT ON CELLULAR BIOENERGETICS IN MYELODYSPLASTIC SYNDROMES
2023 · A. Hrustincova, I. Trsova, et al. · Leukemia Research
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: HEMATOPOIETIC STEM CELLS OF LOWER-RISK MDS PATIENTS WITH RAPID PROGRESSION SHOW QUIESCENT-LIKE CELL STATE SIMILAR TO THAT OF HIGHER-RISK MDS CELLS
2023 · M. Kaisrlikova, Z. Lenertova, et al. · Leukemia Research
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY
2023 · A. Jonasova, L. Minarik, et al. · Leukemia Research
Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: SALVAGE VENETOCLAX COMBINATION THERAPY IN PATIENTS WITH AML TRANSFORMATION AFTER AZACITIDINE THERAPY FAILURE FOR HIGH-RISK MDS – SINGLE-CENTER EXPERIENCE
2023 · L. Minarik, T. Stopka, et al. · Leukemia Research
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MUTATIONS OF SF3B1 GENE AND ITS SIGNIFICANCE ON PATIENTS WITH MYELODYSPASTIC SYNDROMES (MDS)
2023 · Z. Zemanova, T. Aghova, et al. · Leukemia Research
P445: Cryptic Translocation T(5;11)(q35;p15) Resulting in Nup98::nsd1 Gene Fusion in Adults With De Novo Acute Myeloid Leukemia (aml)
2022 · S. Ransdorfova, J. Markova, et al. · HemaSphere
S169: Clinical and Molecular Markers for Predicting Response to Romiplostim Treatment in Lower-risk Myelodysplastic Syndromes
2022 · A. S. Kubasch, A. Giagounidis, et al. · HemaSphere
Pb1921: a Randomized, Double-blind, Phase 3 Study of Tamibarotene/azacitidine Versus Placebo/azacitidine in Newly Diagnosed Adult Patients Selected for Rara-positive Hr-mds (select-mds-1)
2022 · A. DeZern, G. Marconi, et al. · HemaSphere
Topic: AS02-Epidemiology
2021 · A. Jonasova, P. Belohlavkova, et al. · Leukemia Research
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling
2021 · M. Merkerova, J. Klema, et al. · Leukemia Research
[Not Available].
2013 · R Neuwirtová, H Klamová, et al. · PubMed
301 Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and Intermediate-1)
2011 · A. Jonasova, J. Cermak, et al. · Leukemia Research
Works count: 21
Citation count: 13
H-index: 3
I10-index:
Year
Topic
Type